Alexion in €639m bid for Wilson Therapeutics ABA public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics’ Board of Directors. Alexion’s SEK232/share bid would total in an acqusition price … more ➔
Novartis enters SMA race acquiring AveXis for US$8.7bn Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis … more ➔
Blood test predincting Alzheimer’s paves way to earlier therapyA newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis. more ➔
Poor investigator brochures: Resarchers call for standardisationHuman drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by … more ➔
Ose and Boehringer ink €1.1bn deal in immunoncologyFrench Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio … more ➔
Cellectis in offering of US$175m ADS following asset swapFrench allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis. more ➔
Motif Bio to submit NDA for iclaprim Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) … more ➔
Takeda announced bid for Shire Japanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April. more ➔
Roche reports 5 deaths after dosing of HemlibraRoche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect … more ➔
From biorefineries to consumer goodsMore than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies. more ➔
